Results

Results

Changing Lives, With the Evidence to Prove It For patients with drug-resistant major depression, the life-changing power of NeuroStar® TMS is clear. It’s backed by substantial data, including the world’s largest depression Outcomes Registry**.

Proven Depression Relief That Lasts

Graph of response and remission rates for patients.

By clinician rating, 83% of patients responded to an acute course of NeuroStar, and 62% achieved remission.5,22

On a patient-rated scale, 69% of patients achieved response, and 36% achieved remission.5,22

Graph of long term post-acute treatment rates for patients.

The only TMS treatment with demonstrated durability in depression*** through 1 year.8,11

In a naturalistic clinical study in 257 patients who did not benefit from antidepressant medications, NeuroStar Advanced Therapy offered durable effect over 1 year*** following acute treatment.8,11

  • 36.2% of patients received NeuroStar Advanced Therapy reintroduction (average of 16 treatments).2 Long-term durability of effect has not been established in a randomized trial. Trial design used physician-directed standard of care.
  • Consistent response and remission rates were achieved across a broad range of antidepressant treatment resistance.22
  • Patients with both low and high treatment-resistant depression who were treated with NeuroStar Advanced Therapy experienced significant benefits after 4 to 6 weeks of treatment.11

More Clinical Data than Any Other TMS Provider

Real-World Trials Icon

Real-World Trials

NeuroStar’s safety and efficacy is backed by the largest clinical data set of any TMS system for depression.2 The clinically significant antidepressant effect of NeuroStar Advanced Therapy was demonstrated in two large, multisite, randomized, controlled trials.11,19 NeuroStar’s efficacy was also demonstrated in a multisite, real-world, open-label clinical trial in which patients received an acute NeuroStar treatment course.7,11,12,15,17,19

Remission Rate Icon

4x Remission Rate

Clinical results demonstrated an improvement in depression symptoms. In an NIMH-funded, independent, randomized, controlled trial, patients treated with NeuroStar Advanced Therapy were four times more likely to achieve remission compared to patients receiving sham treatment.11 Significant improvement from baseline with NeuroStar Advanced Therapy was observed as early as 2 weeks after treatment and at 4 and 6 weeks (P=0.0006).4

Outcome Registry Patients Icon

16,500+ Patients

Only the NeuroStar® Advanced Therapy Outcomes Registry has data on over 16,500 patients since being initiated in September 2016, making it the largest data set in major depressive disorder. This data is from 118 NeuroStar practice sites.2,6,22

Clinical Studies Icon

65 Clinical Studies

NeuroStar’s commitment to advancing the science of TMS and neurohealth has been demonstrated in over 65 investigator-initiated clinical studies with more than 1,900 patients.

If you’re interested in conducting an Investigator Initiated Trial, please contact Neuronetics Customer Service at 877-600-7555.

Numerous Publications Icon

Numerous Publications

NeuroStar is proven in scientific publicati ons and presentations. Click here for links to publications related to the safety and efficacy of NeuroStar Advanced Therapy.

EmptyShadePNG

Numerous Publications

NeuroStar is proven in scientific publications and presentations. Click here for links to publications related to the safety and efficacy of NeuroStar Advanced Therapy.

The Best Evidence Is a Changed Life

MDD patients often go through years of trial and error with different medications. For those people, the life-changing power of NeuroStar can best be grasped through their own words.

Results

MLB’s Drew Robinson — a TMS Journey

Drew Robinson had reached the peak, playing baseball at the highest level, but inside Drew was suffering. He thought he was out of options, and tried to take his own life.

Drew's NeuroStar Journey